Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evalu
about
Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium studyThe role of hormonal therapy in patients with relapsed high-grade ovarian carcinoma: a retrospective series of tamoxifen and letrozoleUtility of vascular endothelial growth factor inhibitors in the treatment of ovarian cancer: from concept to application.The effects of 17β-estradiol and a selective estrogen receptor modulator, bazedoxifene, on ovarian carcinogenesis.Inhibition of angiogenesis by selective estrogen receptor modulators through blockade of cholesterol trafficking rather than estrogen receptor antagonismA mixed-methods feasibility trial of protein kinase C iota inhibition with auranofin in asymptomatic ovarian cancer patients.New insights on the role of hormonal therapy in ovarian cancerThe rise, fall and subsequent triumph of thalidomide: lessons learned in drug development.Oncogenic CUL4A determines the response to thalidomide treatment in prostate cancerHormone response in ovarian cancer: time to reconsider as a clinical target?Recurrent epithelial ovarian cancer and hormone therapy.Understanding the cross-talk between ovarian tumors and immune cells: mechanisms for effective immunotherapies.Palliative chemotherapy for malignant ascites secondary to ovarian cancer.Angiogenesis inhibitors in the treatment of epithelial ovarian cancer.Monoclonal antibodies therapies for ovarian cancer.Hormonal treatment in recurrent and metastatic gynaecological cancers: a review of the current literature.Expression of estrogen and progesterone receptors across human malignancies: new therapeutic opportunities.Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical Specimens.Endocrine therapy in epithelial ovarian cancer.A phase II study of lenalidomide in platinum-sensitive recurrent ovarian carcinoma.Effect of tamoxifen, methoxyprogesterone acetate and combined treatment on cellular proliferation and apoptosis in SKOV3/DDP cells via the regulation of vascular endothelial growth factor.Prediction of therapy response in ovarian cancer: Where are we now?Cancer of the ovary, fallopian tube, and peritoneum.Thalidomide and lenalidomide for recurrent ovarian cancer: A systematic review of the literature.Cellular and Molecular Changes in MNU-Induced Breast Tumours Injected with PF4 or bFGFOverall survival and post-progression survival are potent endpoint in phase III trials of second/third-line chemotherapy for advanced or recurrent epithelial ovarian cancer.
P2860
Q33551425-9450424F-576F-4155-B584-601D91ED4CFCQ33861668-A2D347B0-4F23-4819-9448-7EC79BD4782BQ35233993-149D4A5E-507F-4E13-A405-33EE48575B70Q35646553-DF676512-1C67-4585-BA98-488331B2B958Q35748908-159D0FFB-4CDE-4E50-894F-AFAEEA93487CQ35954798-D4834C1D-66E9-4DDD-A049-52B343FB1E5FQ36001247-22A40FBF-6268-4985-B66E-9D89166C21CBQ36612613-3208694A-AB1B-4AD9-9648-6C2FA274DEB5Q36833979-EFBC6F31-1E40-49DF-BC5C-54EFE90CFCA1Q36966197-9245A6AA-EB40-43B2-BEAD-F7890D39852AQ37354691-71BE9E10-2B74-432C-8CB5-3EECAFC8A436Q37873924-FA4BB04B-1F2C-470D-A897-C72E93AAAC63Q37987902-B9CF7FF0-89A4-4AB2-BB2F-FDDAD48BCF16Q38071555-0A2B0041-A6D2-46A2-B50A-9B85A05ED321Q38078400-A8174F68-2BE6-4FD2-899D-5FCAB0D83DEAQ38149813-529B1851-4345-4257-A469-98655335A286Q38301592-9C246810-9529-42DC-89BC-A53451871A92Q39028384-C77E2C4F-A18D-4AB1-960C-7BAA18E53AD3Q39038223-0FE2C418-AF9E-4D22-B153-4E0AD07627EAQ39131099-19E3A698-FB10-44EE-8AA1-668F47F40F73Q39232160-19AA516B-B23C-4842-A202-D3A32D812519Q39263260-F53B2F4C-334C-4CA0-BC0C-DF2E23CFD85EQ41266914-72D1D8F2-E202-4771-B3FB-D252E69051E5Q41619260-D2CC9A1C-9C83-4BF9-BCE5-4BCE65C81475Q47559793-49E38271-E136-4B3A-9936-F775FD8B622EQ54951150-D00DA286-F500-46CE-94B4-902344AA7853
P2860
Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evalu
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Randomized phase III trial of ...... ane chemotherapy with an evalu
@en
Randomized phase III trial of ...... ane chemotherapy with an evalu
@nl
type
label
Randomized phase III trial of ...... ane chemotherapy with an evalu
@en
Randomized phase III trial of ...... ane chemotherapy with an evalu
@nl
prefLabel
Randomized phase III trial of ...... ane chemotherapy with an evalu
@en
Randomized phase III trial of ...... ane chemotherapy with an evalu
@nl
P2093
P921
P1433
P1476
Randomized phase III trial of ...... necologic Oncology Group Study
@en
P2093
Iouri Ivanov
Jean A Hurteau
Kathleen M Darcy
Krishnansu S Tewari
Kristine Zanotti
Mark F Brady
Michael L Pearl
Pamela Edmonds
Robert S Mannel
William P McGuire
P304
P356
10.1016/J.YGYNO.2010.08.002
P407
P577
2010-09-17T00:00:00Z